Merck CEO high on Cubist acquistion
Jeffrey Clark - Posted: 12/18/2014
Merck CEO Ken Frazier talks synergy and opportunities following the companys $9.5B takeover of Cubist Pharmaceuticals.
A new leading brand in medical devices, Zimmer Biomet
Jeffrey Clark - Posted: 12/17/2014
A new dominant medical device company is born, no rebranding required. Last month, Zimmer announced plans to change its name to Zimmer Biomet upon closing its acquisition of former competitor Biomet in early 2015.  The orthopedic device maker said th[...]
The never-ending cycle of patent cliffs
Jeffrey Clark - Posted: 12/16/2014
Patent expirations are nothing new and never ending.  Every drug eventually falls off patent losing ground to cost effective generic competition.  The past decade has seen a wave of significant patent expirations that have pummeled the likes of Pfize[...]
Burrill: 2014 poised to set significant deal-making records
Jeffrey Clark - Posted: 12/15/2014
Actavis agreement to acquire Allergan for $66 billion is likely the cherry on top of the most significant year ever for mergers and acquisitions for the life sciences industry.  The Allergan-Actavis agreement sent 2014 totals past $340B in the first [...]
Billionaire champions new cell biology institute in Seattle
Jeffrey Clark - Posted: 12/12/2014
Software billionaire Paul Allen has made a splash at this weeks  American Society for Cell Biologys annual meeting in Philadelphia, committing $100 million to create a new institute in Seattle focusing on the mechanics of human cell biology. The Alle[...]
Valeant pivots, to focus on performance rather than growth by acquisition
Jeffrey Clark - Posted: 12/11/2014
Losing the battle for Allergan has taken a toll on Valeant Pharmaceuticals.  The company today announced that it will abandon its growth-by-acquisitions strategy for the time being to focus on reducing debt, raising its stock price and potentially re[...]
How Actavis looks to integrate Forest, Warner Chilcott, Allergan
Jeffrey Clark - Posted: 12/9/2014
Allergans longstanding saga, that seemed to stretch for the entirety of 2014, has come to an end.  While the company did manage to fend off an unwanted deal with Valeant, Allergan still faces a cataclysm of change in 2015 following a $66B deal by Act[...]
Device tax repeal at forefront, led by Advamed, GOP
Jeffrey Clark - Posted: 12/9/2014
The medical device tax and FDA approval delays remain major factors influencing an increasing number of companies to launch products outside the US, said AdvaMed President and CEO Stephen Ubl in a recent interview.  The easy availability of venture c[...]
Novartis CEO details strategy, asset swap with GSK and Lilly
Jeffrey Clark - Posted: 12/8/2014
Novartis and GSK are in the process of reworking their businesses.  Earlier this year, the two agreed to essentially swap assets and now those reorganizations are in full force. On CNBC, Novartis CEO Joe Jimenez announces the companys intention to fo[...]
Gilead buys FDA priority review voucher from Knight Therapeutics
Jeffrey Clark - Posted: 12/8/2014
For the first time since the FDA began a voucher program several years ago to encourage development of drugs to treat neglected tropical diseases, a drug maker has sold a voucher to another company. And the deal may help the pharmaceutical industry e[...]
Changing the world: Google, nanoparticles and wearable diagnostics
Jeffrey Clark - Posted: 12/5/2014
Googles move into medical technology has accelerated. Earlier this year, the technology giant partnered with Novartis in a bid to create a smart, wearable contact lens to measure blood glucose in diabetic patients.  The company had also recently inve[...]
Theranos CEO changing diagnostic testing, youngest billionaire in the world
Jeffrey Clark - Posted: 12/4/2014
Elizabeth Holmes left Stanford University at 19 with a plan to start her own company. For money, she cashed out the funds her parents had saved for tuition. Now, she counts billionaire Larry Ellison as an investor and has former secretaries of state [...]
Johnson and Johnson sets sights on Ebola vaccine, partners with GSK
Jeffrey Clark - Posted: 12/3/2014
Paul Stoffels, chief scientific officer at Johnson & Johnson, talks about the companys plans to have 250,000 doses of experimental Ebola vaccine ready for clinical trials in May. Johnson & Johnson has set a goal to produce at least 1 million doses of[...]
Fact or fiction: Tufts estimates $2.6B cost to develop a drug
Jeffrey Clark - Posted: 12/1/2014
The cost of developing a new drug has more than doubled in the past 10 years, now estimated to be more than to $2.5 billion, according to a study released today by the Tufts Center for the Study of Drug Development (CSDD).  Back in 2003, Tufts estima[...]
Would you let a robot do surgery on your brain?
Jeffrey Clark - Posted: 11/27/2014
Cool technology meets overwhelming hypothetical question? Researchers at Vanderbilt University have been developing a technology for a robot to perform surgery on the deepest sections of the human brain, as a less invasive treatment for epilepsy. Com[...]
Research pipelines still all about cancer
Jeffrey Clark - Posted: 11/26/2014
The Pharmaceutical Research and Manufacturers of America (PhRMA) reported that 771 drugs and vaccines for cancer are being developed by US companies. The roster includes almost 100 treatments for lung cancer, 50 for ovarian cancer, more than 75 for l[...]
AbbVie leadership under scrutiny for Shire blunder
Jeffrey Clark - Posted: 11/23/2014
AbbVie wins the Shifting Gears award for 2014 with its on again, off again bid to acquire Shire for $54 billion.   Now, some are calling into question the credibility of AbbVies management for the blunder. AbbVie announced its intent to acquire Shire[...]
Edwards CEO on new heart valve technology
Jeffrey Clark - Posted: 11/19/2014
Edwards Lifesciences CEO Michael Mussallem talks with CNBC about how his company is helping patients recover quicker from heart valve surgery.
Next Sanofi CEO? The candidates
Jeffrey Clark - Posted: 11/19/2014
Its been two weeks since Sanofi let go of CEO Chris Viehbacher, ending an 8-year tenure at the leading drug company. Viehbacher leaves behind a trail of acquisitions, job cuts, expansion and R&D reform. More importantly, he left in his wake a tenuous[...]
Actavis, Allergan CEOs on CNBC; Ackman walks away with $2B
Jeffrey Clark - Posted: 11/18/2014
Bill Ackman’s Pershing Square hedge fund is set to receive a $2 billion consolation prize, even after partner Valeant Pharmaceuticals walks away from its hostile takeover bid for Allergan. Yesterday, Allergan announced a deal with Actavis for almost [...]
Actavis, Allergan look to push Valeant out of the picture
Jeffrey Clark - Posted: 11/17/2014
Actavis is nearing a deal to acquire Allergan in a move that could help shield Allergan from a hostile takeover by Valeant Pharmaceuticals. The Actavis and Allergan boards are expected to meet this week to review a cash & stock takeover. Ironically, [...]
Hologic CEO joins CNBC in studio, talks medical device tax
Jeffrey Clark - Posted: 11/17/2014
Hologic president & CEO Steve MacMillan joins CNBC in studio to share his opinion on the unintended consequences of the Affordable Care Act and the likelihood of overturning the medical device tax.
Pfizer CEO spurns US Treasury: We can still do an inversion deal
Jeffrey Clark - Posted: 11/13/2014
Pfizer CEO Ian Read makes no apologies for his interest in working a deal to move his tax home overseas.   Despite the U.S. governments attempt to discourage tax inversionslike the one Pfizer would have achieved by buying AstraZeneca Read says he is[...]
Johnson and Johnson CEO on CNBC in support of veterans
Jeffrey Clark - Posted: 11/13/2014
Johnson & Johnson CEO Alex Gorsky was on CNBCs Street Signs last week affirming the companys support for the American Corporate Partners (ACP)s public service campaign designed to increase awareness of ACP AdvisorNet, which offers business leaders a [...]
A detailed account of the firing of Sanofi CEO Chris Viehbacher
Jeffrey Clark - Posted: 11/10/2014
Bloomberg publishes a detailed minute by minute account of Sanofi CEO Chris Viehbachers firing. Was he not French enough?
Merck CEO high on Cubist [...]
Merck CEO Ken Frazier talks synergy and opportunities following the company’s $9.5B takeover of Cubi[...]
Johnson and Johnson sets [...]
Paul Stoffels, chief scientific officer at Johnson & Johnson, talks about the company’s plans to hav[...]
Novartis CEO details stra[...]
Novartis and GSK are in the process of reworking their businesses. Earlier this year, the two agree[...]
Theranos CEO changing dia[...]
Elizabeth Holmes left Stanford University at 19 with a plan to start her own company. For money, she[...]
Edwards CEO on new heart [...]
Edwards Lifesciences CEO Michael Mussallem talks with CNBC about how his company is helping patients[...]